Innate Pharma (NASDAQ: IPHA) — Company Overview, News & Financial Data
Innate Pharma develops therapeutic antibodies targeting cancer, aiming to improve oncology treatment outcomes.
Innate Pharma
Innate Pharma (EURONEXT:IPHA), (NASDAQ:IPHA) specializes in the development of innovative therapeutic antibodies that aim to improve the treatment of cancer. This French biotech company is focused on harnessing the immune system’s power to develop novel, first-in-class therapeutic antibodies for oncology. Innate Pharma's pipeline includes candidates in clinical and preclinical stages that target immune checkpoints and other receptors to stimulate the immune response against cancer. The company's projects are a mix of proprietary programs and collaborations with major pharmaceutical companies, aiming to address unmet medical needs in oncology. Innate Pharma's objective is to leverage its expertise in immunology and antibodies to bring new treatment options to cancer patients.
Snapshot
Operations
Products and/or services of Innate Pharma
- Monalizumab, an innovative immune checkpoint inhibitor targeting NKG2A receptors on NK and CD8 T cells, shows promise in multiple solid tumor types.
- Lacutamab, an antibody targeting KIR3DL2 for the treatment of cutaneous T-cell lymphoma and other potential indications.
- IPH6101/SAR443579, a collaboration project for natural killer cell engagers targeting various cancers, showcases their expertise in NK cell activation.
- Avdoralimab, an anti-C5aR blocker with potential in treating inflammatory diseases and certain cancers, highlights their interest in immune modulation.
- IPH5201, an antibody targeting CD39, which plays a role in immunosuppression in the tumor microenvironment, indicating their investment in cancer immunotherapy.
Innate Pharma executive team
- Jonathan E. DickinsonCEO & Director
- Yannis MorelExecutive VP & COO
- François RomagnéFounder
- Marc BonnevilleFounder
- Jean Jacques FourniéFounder
- Alessandro MorettaFounder
- Frederic LombardSenior VP & CFO
- Stephanie CornenVice President of Investor Relations, Communication & Commercial Strategy
- Odile BelzunceVP, Chief of Compliance & Operations Officer and Interim Head of HR
- Claire de Saint BlanquatVP of Legal & Corporate Affairs and Secretary of the Supervisory Board
Latest news about Innate Pharma
Innate Pharma delays PACIFIC-9 trial data to 2027
United StatesInnate Pharma posts €5.7 million H1 revenue
United StatesInnate Pharma plans Phase 3 trial after Sobi deal
United StatesInnate Pharma completes 76 patient phase one enrollment
United StatesInnate Pharma eprorts €2.6M Q1 revenue, maintains cash runway to end-Q3 2026
United StatesInnate Pharma reports 2025 financial results amid strategic restructuring and pipeline realignment
United States
Key financials
Reported results for Innate Pharma, in EUR.
- Market cap
- 165.3M
- Revenue (TTM)
- 9.8M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.6
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 2.8M | -53.4M | -49.2M | |
| 12.6M | -51.6M | -49.5M | |
| 51.9M | -12.7M | -7.6M | |
| 57.7M | -57.4M | -58.1M |